Welcome to our dedicated page for Adc Therapeutics Sa SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, drug-development milestones, and detailed R&D spending make ADC Therapeutics鈥� SEC documents some of the most technical in biotech. If you have ever searched "ADCT SEC filings explained simply" or wondered where to locate an "ADCT quarterly earnings report 10-Q filing" that actually highlights pipeline progress, you know the challenge.
Stock Titan solves it. Our AI parses every ADCT annual report 10-K, 10-Q, and 8-K the moment it hits EDGAR, then delivers plain-English summaries of cash runway, trial readouts, and collaboration terms鈥攏o biotech PhD required. Need "ADCT Form 4 insider transactions real-time" or alerts on "ADCT executive stock transactions Form 4" before markets react? We stream them instantly and add clear context. You can also compare compensation details through the "ADCT proxy statement executive compensation" section, while our earnings report filing analysis flags changes in R&D intensity quarter over quarter.
Whether you track "ADCT 8-K material events explained" for regulatory updates, want an "ADCT insider trading Form 4 transactions" history to gauge management conviction, or simply prefer an "ADCT annual report 10-K simplified" view that surfaces key risk factors, every disclosure lives here with AI-powered highlights, trend graphs, and exportable data. Understanding ADCT SEC documents with AI means spending minutes, not hours, to spot the information that moves oncology-focused valuations.
Redmile Group and affiliated entities report significant holdings in ADC Therapeutics SA. The Schedule 13G/A discloses that Redmile Group, LLC and Jeremy C. Green collectively have shared voting and dispositive power over 15,666,731 common shares, representing 14.0% of the outstanding common stock on the basis described in the filing. One affiliated fund, RedCo II Master Fund, L.P., is reported with shared power over 13,145,712 shares (11.7%). The filing states these shares are held by private investment vehicles managed by Redmile and that both Redmile Group and Mr. Green disclaim direct beneficial ownership except to the extent of any pecuniary interest. The percentage calculations use the issuer's reported outstanding shares plus a recent private placement.
ADC Therapeutics SA filed a Form S-8 on August 12, 2025 to register 4,850,000 additional common shares (par value CHF 0.08) for issuance under the ADC Therapeutics SA 2019 Equity Incentive Plan. The filing incorporates by reference prior Form S-8 registrations filed on March 15, 2023 and June 30, 2022 and references periodic reports filed in 2025.
Exhibits listed include amended and restated articles, a Swiss counsel opinion, the consent of PricewaterhouseCoopers SA, the amended plan and a filing fee table.
ADC Therapeutics reported consolidated revenue of $18.8 million for the quarter and $41.9 million for the six months, driven by U.S. product sales of ZYNLONTA and increased license/royalty income. The company recorded a net loss of $56.6 million for the quarter and $95.2 million for the six months, reflecting higher R&D spending and a $13.1 million charge for restructuring and impairments tied to a plan to close the UK facility and reduce global headcount by approximately 30%.
Liquidity was strengthened by a June private placement that generated gross $100.0 million (net $93.1 million), leaving cash and cash equivalents at $264.6 million. Material longer-term obligations include a deferred royalty obligation (fair value ~$312.0 million, carrying balance rolled to $340.4 million in the rollforward) and senior secured term loans with a carrying value of $114.5 million and an effective interest rate of 16.15%. Shareholders' deficit was $(199.2) million at June 30, 2025.
ADC Therapeutics SA reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company filed a Current Report on Form 8-K to attach that press release as Exhibit 99.1, and the filing also includes a Cover Page Interactive Data File as Exhibit 104.
The filing states that the information in Item 2.02 and Exhibit 99.1 is incorporated by reference but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The report is signed on behalf of the company by Jose Carmona, Chief Financial Officer. The 8-K itself does not include the detailed financial tables or results within the body of the filing.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
